ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Stock Based Compensation

Last Annual Value

12.33M

3-Year CAGR

233%

5-Year CAGR

%

10-Year CAGR

%

ZB

Zura Bio Limited Competitors Analysis of Stock Based Compensation

ZURA · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
12.33M
8.5%N/AN/A 
11.80M
-11.4%12.9%N/A
12.68M
-2.7%29.7%N/A
35.56M
N/A74.2%N/A
1.96M
12.1%14.1%-1.5%
19.61M
14.4%50.7%N/A
3.95M
132.8%N/AN/A
0.00
N/AN/AN/A
13.05M
-5.2%34.6%N/A
6.45M
8.9%27.6%N/A
4.68M
-3.0%-2.2%-0.7%
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1